[New drug approval: Encorafenib-metastatic colorectal cancers with BRAF V600E mutation after systemic chemotherapy]

Bull Cancer. 2020 Nov;107(11):1086-1088. doi: 10.1016/j.bulcan.2020.08.012. Epub 2020 Oct 9.

[Article in French]

Authors

Alice Boilève¹, Emmanuelle Samalin²

Affiliations

¹ Gustave Roussy Cancer Campus, département d'oncologie digestive, Villejuif, France. Electronic address: [email protected].
² Institut du Cancer de Montpellier, département d'oncologie digestive, Montpellier, France.

PMID: 33046237
DOI: 10.1016/j.bulcan.2020.08.012

No abstract available

Keywords: BRAF V600E; Cancer colorectal; Cetuximab; Colorectal cancer; Encorafenib; Metastases; Métastases.

Publication types

Letter
News

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Benzimidazoles / administration & dosage
Benzimidazoles / adverse effects
Carbamates / adverse effects
Carbamates / therapeutic use*
Cetuximab / administration & dosage
Cetuximab / adverse effects
Clinical Trials, Phase III as Topic
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / genetics*
Colorectal Neoplasms / mortality
Drug Approval*
Humans
Mutation
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
Proto-Oncogene Proteins B-raf / genetics*
Randomized Controlled Trials as Topic
Sulfonamides / adverse effects
Sulfonamides / therapeutic use*

Substances

Benzimidazoles
Carbamates
Sulfonamides
binimetinib
encorafenib
Proto-Oncogene Proteins B-raf
Cetuximab